Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Phase 3 Study of Loncastuximab Tesirine, an Anti-CD-19 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT Number:
NCT04384484
Phase:
III
Protocol Type:
Treatment
Age Group:
Adult
Disease Sites:
Non-Hodgkin's Lymphoma
Study Objectives:
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
If you would like to contact a MUSC study team member to learn more information about this study, click
HERE.